Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

BACKGROUND: In pulmonary arterial hypertension (PAH), combination therapy is an important treatment strategy. Although randomized controlled trial data are available to support the combination of two therapies, data regarding triple combination therapy are few. OBJECTIVE: The phase III GRIPHON trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Coghlan, J. Gerry, Channick, Richard, Chin, Kelly, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Gaine, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772136/
https://www.ncbi.nlm.nih.gov/pubmed/29307087
http://dx.doi.org/10.1007/s40256-017-0262-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772136/
https://www.ncbi.nlm.nih.gov/pubmed/29307087
http://dx.doi.org/10.1007/s40256-017-0262-z

Ejemplares similares